AbbVie wrote off $3.5 billion on the schizophrenia treatment from its Cerevel buyout, after the drug failed two Phase 2 studies. The drug was expected to be a major competitor with Bristol Myers' Cobenfy endpts.com/abbvie-write... - ThreadSky

maxgelman.bsky.social • 48 days ago

AbbVie wrote off $3.5 billion on the schizophrenia treatment from its Cerevel buyout, after the drug failed two Phase 2 studies. The drug was expected to be a major competitor with Bristol Myers' Cobenfy

https://endpts.com/abbvie-writes-off-3-5b-on-cerevel-drug-after-phase-2-failures/

Comments

Posting Rules

Comments

Posting Rules

Reply